



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Acazicolcept

Cat. No.:	HY-P99420
CAS No.:	2797026-97-0
Target:	CD28
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities ^[1] .								
In Vivo	<p>Acazicolcept (267-400 µg/mouse; i.p.; twice a week; for 6 weeks) decreases dermal and pulmonary fibrosis and alleviates pulmonary hypertension^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>Six-week-old female BALB/c mice induced by hypochlorous acid (HOCL)^[1]</td></tr><tr><td>Dosage:</td><td>267 µg/mouse and 400 µg/mouse</td></tr><tr><td>Administration:</td><td>i.p.; twice a week; for 6 weeks</td></tr><tr><td>Result:</td><td>Induced a significant decrease in dermal thickness, collagen content, myofibroblast number, and inflammatory infiltrates characterized by B cells, T cells, neutrophils, and macrophages.</td></tr></table>	Animal Model:	Six-week-old female BALB/c mice induced by hypochlorous acid (HOCL) ^[1]	Dosage:	267 µg/mouse and 400 µg/mouse	Administration:	i.p.; twice a week; for 6 weeks	Result:	Induced a significant decrease in dermal thickness, collagen content, myofibroblast number, and inflammatory infiltrates characterized by B cells, T cells, neutrophils, and macrophages.
Animal Model:	Six-week-old female BALB/c mice induced by hypochlorous acid (HOCL) ^[1]								
Dosage:	267 µg/mouse and 400 µg/mouse								
Administration:	i.p.; twice a week; for 6 weeks								
Result:	Induced a significant decrease in dermal thickness, collagen content, myofibroblast number, and inflammatory infiltrates characterized by B cells, T cells, neutrophils, and macrophages.								

REFERENCES

[1]. Cindy Orvain, et al. Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. *Arthritis Res Ther.* 2022 Jan 5;24(1):13.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA